NASDAQ:ADMP - Adamis Pharmaceuticals Stock Price, Forecast & News

Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP."

Adamis Pharmaceuticals Corp (NASDAQ:ADMP) posted its earnings results on Tuesday, November, 12th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.06. The specialty pharmaceutical company earned $5.90 million during the quarter, compared to the consensus estimate of $6.55 million. Adamis Pharmaceuticals had a negative return on equity of 90.00% and a negative net margin of 175.77%. View Adamis Pharmaceuticals' Earnings History.

Adamis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Adamis Pharmaceuticals.

4 equities research analysts have issued 1 year price targets for Adamis Pharmaceuticals' shares. Their forecasts range from $1.10 to $6.00. On average, they anticipate Adamis Pharmaceuticals' share price to reach $3.70 in the next twelve months. This suggests a possible upside of 483.0% from the stock's current price. View Analyst Price Targets for Adamis Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamis Pharmaceuticals.

Headlines about ADMP stock have trended very negative on Sunday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Adamis Pharmaceuticals earned a media sentiment score of -3.8 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Adamis Pharmaceuticals.

Some companies that are related to Adamis Pharmaceuticals include Tyme Technologies (TYME), Avenue Therapeutics (ATXI), Northwest Biotherapeutics (NWBO), ContraFect (CFRX), OASMIA PHARMACE/ADR (OASM), Marinus Pharmaceuticals (MRNS), Harrow Health (HROW), Selecta Biosciences (SELB), Aptinyx (APTX), vTv Therapeutics (VTVT), Adamas Pharmaceuticals (ADMS), Mustang Bio (MBIO), Verastem (VSTM), Obseva (OBSV) and NuCana (NCNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamis Pharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Trevena (TRVN), Verastem (VSTM), Sorrento Therapeutics (SRNE), Agile Therapeutics (AGRX), Novavax (NVAX), Amarin (AMRN), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and Exelixis (EXEL).

Adamis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (1.02%). Company insiders that own Adamis Pharmaceuticals stock include David J Marguglio, Dennis J Phd Carlo, Karen K Daniels, Robert B Rothermel, Robert O Hopkins and Ronald B Moss. View Institutional Ownership Trends for Adamis Pharmaceuticals.

ADMP stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC. View Insider Buying and Selling for Adamis Pharmaceuticals.

Shares of ADMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMP stock can currently be purchased for approximately $0.63.

Adamis Pharmaceuticals has a market capitalization of $39.12 million and generates $15.09 million in revenue each year. The specialty pharmaceutical company earns $-39,010,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Adamis Pharmaceuticals employs 152 workers across the globe.View Additional Information About Adamis Pharmaceuticals.

The official website for Adamis Pharmaceuticals is http://www.adamispharmaceuticals.com/.

Adamis Pharmaceuticals' mailing address is 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The specialty pharmaceutical company can be reached via phone at 858-997-2400 or via email at [email protected]